Since the CYP3A5*3, *6, and *7 variants lead to a non-functional CYP3A5 enzyme, individuals carrying these variants may have reduced cortisol metabolism and sodium retention, potentially reducing their risk of hypertension compared to CYP3A5*1 carriers (Lamba et al., 2002; Wojnowski, 2004; Xi et al., 2011; Zhang et al., 2010). This evidence concerns the gene CYP3A5 and hypertensive disorder.